-
Study aim
-
Determining and comparing the effectiveness of "Intraconazole with fluticasone", "Doxycycline with fluticasone", and "Fluticasone spray alone" in the treatment of chronic rhinosinusitis with nasal polyps
-
Design
-
The randomized, Single-blind clinical trial, with the parallel groups, Phase 2 on 108 patients
-
Settings and conduct
-
In this randomized Single-blind clinical trial study, 108 eligible patients referred to Kashani and Al-Zahra hospitals in Isfahan will be included in the study and randomly divided into 3 groups. Patients in the first group will be prescribed itraconazole with fluticasone, in the second group "doxycycline with fluticasone", and in the third group "fluticasone spray alone", then the symptoms of chronic rhinosinusitis will be compared between the three groups.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria include age 15-65 years, with chronic rhinosinusitis, more than 6 months of chronic rhinosinusitis, no medication to control chronic rhinosinusitis in a recent month, and consent to participate in the study.
Exclusion criteria include diabetes, endocrine-metabolic diseases, immunodeficiency diseases, allergy to the studied drugs, and the incidence of hepatic complications due to using intraconazole.
-
Intervention groups
-
Intervention group 1: Patients in this group will receive doxycycline 100 mg twice a day, along with flomist spray intranasally (one puff per nostril every 12 hours).
Intervention group 2: Patients in this group will receive only flomist spray intranasally (one puff per nostril every 12 hours).
Intervention group 3: Patients in this group will receive two capsules of itraconazole 100 mg daily in divided doses, along with flomist spray intranasally (one puff in each nostril every 12 hours).
-
Main outcome variables
-
Symptoms of chronic rhinosinusitis